News TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-26 EDT			5-day change	1st Jan Change
2.922 ^USD	-4.21%		-6.06%	-58.38%

04-15	TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	CI
04-08	TFF Pharmaceuticals Files Equities Shelf	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	04-16	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	04-15	AQ
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	04-15	CI
TFF Pharmaceuticals Files Equities Shelf	04-08	MT
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	03-28	AQ
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	03-28	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating	03-28	MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call	03-27
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	03-27	AQ
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	03-27	CI
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	03-25	AQ
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	03-20	MT
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	03-20	AQ
TFF Pharmaceuticals Announces Update on Clinical Programs	03-20	AQ
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	03-20	CI
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024	03-14	AQ
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference	01-24	AQ
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	01-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Summary

Filters